FIORINAL
LOE ApproachingNDAORALTABLET
Approved
May 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FIORINAL is an oral tablet small-molecule analgesic combination product approved in 1976, currently marketed by AbbVie. The exact mechanism of action and indications are not specified in available data, but the product is positioned as a legacy pain/headache therapeutic. It represents a mature asset with approaching loss of exclusivity.
LOE Approaching
This legacy product faces moderate competitive pressure (30% index) with minimal linked job openings, suggesting a small, stable team preparing for post-LOE transition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FIORINAL represents a legacy franchise with minimal hiring activity (0 linked jobs), indicating a small, mature team focused on maintaining market share rather than expansion. Career growth on this product is limited; professionals should expect stability but limited advancement opportunities as the product approaches loss of exclusivity.
Brand ManagerField Sales Representative
Worked on FIORINAL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.